ARCA BIOPHARMA INC (ABIO) Stock Price, Forecast & Analysis
NASDAQ:ABIO • US00211Y5069
ABIO Key Statistics, Chart & Performance
The current stock price of ABIO is 2.4 USD. In the past month the price decreased by -22.83%. In the past year, price increased by 16.57%.
ABIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ABIO. When comparing the yearly performance of all stocks, ABIO is a bad performer in the overall market: 75.71% of all stocks are doing better.
ABIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABIO. While ABIO has a great health rating, there are worries on its profitability.
ABIO Financial Highlights
Over the last trailing twelve months ABIO reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -13.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.27% | ||
| ROE | -22.1% | ||
| Debt/Equity | 0 |
ABIO Forecast & Estimates
ABIO Ownership
ABIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABIO
Company Profile
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
Company Info
ARCA BIOPHARMA INC
10170 Church Ranch Way, Suite 100
Westminster COLORADO 80021 US
CEO: Michael R. Bristow
Employees: 4
Phone: 17209402200
ARCA BIOPHARMA INC / ABIO FAQ
What does ABIO do?
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
What is the current price of ABIO stock?
The current stock price of ABIO is 2.4 USD. The price decreased by -4% in the last trading session.
What is the dividend status of ARCA BIOPHARMA INC?
ARCA BIOPHARMA INC (ABIO) has a dividend yield of 67.21%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of ABIO stock?
ABIO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ARCA BIOPHARMA INC (ABIO) based on its PE ratio?
ARCA BIOPHARMA INC (ABIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
Can you provide the number of employees for ARCA BIOPHARMA INC?
ARCA BIOPHARMA INC (ABIO) currently has 4 employees.
Who owns ARCA BIOPHARMA INC?
You can find the ownership structure of ARCA BIOPHARMA INC (ABIO) on the Ownership tab.